Business Overview: Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

---

Executive Summary

Acrivon Therapeutics, Inc. is a clinical-stage precision oncology company distinguished by its proprietary functional proteomics biomarker platform, AP3 (Acrivon Predictive Precision Proteomics), which measures actual protein activity levels within tumors — rather than relying solely on DNA/genomic mutation status — to identify patients most likely to respond to targeted DNA damage response (DDR) pathway therapies. The company's lead candidate, ACR-368 (prexasertib), a CHK1/CHK2 kinase inhibitor, is being developed in combination with the AP3 platform to select and treat ovarian and endometrial cancer patients whose tumors show the specific protein activity signatures the biomarker identifies as most likely to respond.

---

1. Core Business Model & How They Work

Acrivon's core differentiation lies in pairing a DDR-targeted oncology drug candidate with a proprietary companion biomarker platform designed to identify likely responders based on functional protein activity rather than genomic mutation status alone, aiming to improve clinical trial success rates and eventual real-world treatment response rates.

[ AP3 Functional Proteomics Biomarker Platform ]
     ➡ [ Identify Tumors with Target Protein Activity Signatures ]
     ➡ [ Match to ACR-368 (CHK1/CHK2 Inhibitor) Treatment ]
     ➡ [ Biomarker-Selected Clinical Trials (Ovarian, Endometrial Cancer) ]
     ➡ [ FDA Approval with Companion Diagnostic / Partnership ]

Key Operational Drivers

1. Functional Proteomics Patient Selection: Unlike genomic-only biomarker approaches used by many DDR-focused competitors, Acrivon's AP3 platform measures actual protein pathway activity, aiming to more accurately identify which patients will respond to CHK1/CHK2 inhibition regardless of the specific underlying genomic mutation.
2. Biomarker-Enriched Clinical Trial Design: By pre-selecting patients likely to respond using AP3, Acrivon aims to improve the statistical odds of clinical trial success compared to less selective, all-comers trial designs common in oncology drug development.
3. Dual Value Proposition — Drug and Diagnostic: The AP3 platform itself represents a potentially valuable diagnostic and drug-development tool beyond ACR-368 alone, capable of being applied to identify responders for other DDR-pathway therapies as well.

---

2. Competitive Landscape

                Genomic-Biomarker DDR Oncology              Functional-Proteomics-Selected DDR Oncology
                              │                                          │
      Repare Therapeutics ────┼──────                          Acrivon Therapeutics (ACRV)
      (CHK1/ATR inhibitors,   │                                (AP3 functional proteomics +
       genomic biomarkers) ───┤                                 ACR-368 CHK1/CHK2 inhibitor)
      Zentalis Pharmaceuticals │
      (WEE1 inhibitor) ────────┤
      Artios Pharma ───────────┤
                              │
      ──────────────────────── ┼─────────────────────────────────────

Competitors by Domain

DNA Damage Response (DDR) Pathway Oncology

• Key Competitors: Repare Therapeutics (CHK1/ATR inhibitors using largely genomic biomarker selection), Zentalis Pharmaceuticals (WEE1 inhibitor programs), and Artios Pharma (DDR-focused pipeline), among other DDR-targeted oncology developers.
• Dynamics: Most competitors in the DDR space rely primarily on genomic mutation status (e.g., specific gene alterations) to select patients, whereas Acrivon's functional proteomics approach aims to capture a broader and potentially more accurate population of likely responders by directly measuring pathway protein activity, a key scientific differentiation point.

---

3. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Proprietary functional biomarker platform: AP3's protein-activity-based patient selection approach is scientifically differentiated from genomic-only competitor biomarker strategies and is protected by patents covering both the diagnostic methodology and its application to specific drug candidates.
• Improved clinical trial success probability: Biomarker-enriched trial design theoretically improves the odds of demonstrating statistically significant efficacy versus less selective trial populations.
• Platform extensibility: The AP3 platform's potential applicability beyond ACR-368 to other DDR-pathway therapies could create additional pipeline or partnership value beyond the lead program alone.

Strategic Risks & Vulnerabilities

1. Clinical validation risk for a novel biomarker approach: The AP3 platform's functional proteomics methodology, while scientifically compelling, must still prove its predictive value in large, controlled clinical trials to gain regulatory and clinical acceptance.
   • Mitigation Strategy: Rigorous biomarker validation built directly into ongoing ACR-368 clinical trials in ovarian and endometrial cancer.
2. Competition from well-funded DDR-focused rivals: Repare Therapeutics, Zentalis Pharmaceuticals, and Artios Pharma are all pursuing related DDR-pathway targets with substantial capital and clinical resources.
   • Mitigation Strategy: Emphasize the differentiated precision of the AP3 platform as a competitive advantage in patient selection and trial design efficiency.
3. Regulatory complexity of companion diagnostic development: Pairing a drug with a novel companion diagnostic biomarker adds regulatory and commercial complexity beyond a standard drug approval pathway.
   • Mitigation Strategy: Early and ongoing engagement with regulators on companion diagnostic development requirements alongside the therapeutic candidate.

---

4. Financial Overview & Performance Matrix

---

5. Summary Conclusion

Acrivon Therapeutics is pursuing a scientifically differentiated precision oncology strategy, pairing its CHK1/CHK2 inhibitor ACR-368 with a proprietary functional proteomics biomarker platform, AP3, designed to identify likely responders based on actual protein activity rather than genomic mutation status alone — a potentially more accurate patient selection approach than the genomic biomarkers used by most DDR-pathway competitors.

The company's central strategic question is whether the AP3 platform's functional proteomics approach can demonstrate superior predictive accuracy in large-scale clinical trials, validating both ACR-368's efficacy in biomarker-selected ovarian and endometrial cancer patients and the broader scientific premise that functional protein activity outperforms genomic status alone in guiding DDR-targeted cancer therapy.